A property improves the chances of responding to colon cancer for treatment

Data from an experiment for the “Tecentriq” immunotherapy, produced by the company “Roch”, offered at a recent medical meeting, showed that the addition to surgery after surgery after surgery with some patients whose colon cancer led to the lymph nodes to a decline in the possibility of the disease and death with 50%. Patients participating in the study suffered from crops that arose as a result of a genetic defect, known as ‘DNA reform defect in DNA’, and about 15% of patients with colon cancer suffer from tumors with this kind, and their cases of chemotherapy do not respond well. “Our study results are great progress in the assistant treatment of the third phase of colon cancer associated with the disruption of the mismatch in DNA, and will now change the treatment of this type of cancer.” The data was offered at the American Clinical Oncology Association meeting, which concluded earlier this week. The study included 712 colon cancer related to the disruption of the mismanagement in DNA in the third phase, which underwent tumor removal operations and had cancer cells in the lymph nodes. Half of the study participants have a chemical treatment with ‘Tesenterick’, which activates the immune system to attack and eliminate cancer cells, for six months, followed by immunotherapy alone for another six months. The other half of the patients received 12 months chemotherapy, and the benefit of “thesentery” was observed, even in older patients and patients who are most at risk.